Compositions and methods for treating metabolic dysfunction-associated steatotic liver diseases
Lactobacillus paracasei with vitamin B5 modifies gut microbiota to treat and prevent MASLD and MASLD-HCC, addressing the inadequacies of current treatments by effectively suppressing liver disease and cancer progression.
WO2026118874A1 Publication Date: 2026-06-11THE CHINESE UNIVERSITY OF HONG KONG
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- THE CHINESE UNIVERSITY OF HONG KONG
- Filing Date
- 2025-11-20
- Publication Date
- 2026-06-11
AI Technical Summary
⚠Technical Problem
There is a pressing need for new methods and compositions to treat metabolic dysfunction-associated steatotic liver diseases (MASLD) and hepatocellular carcinoma (HCC) associated with MASLD, as current treatments are inadequate and pose significant health risks.
⚗Method used
A composition comprising Lactobacillus paracasei, optionally with vitamin B5, is administered to modify gut microbiota, improving liver health and reducing the risk or treating MASLD and MASLD-HCC, formulated in various forms for oral ingestion.
🎯Benefits of technology
The composition effectively suppresses liver disease progression and cancer cell proliferation, offering a safe and effective treatment and prevention strategy for MASLD and MASLD-HCC.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 1 Figure 2
Abstract
Provided is a composition comprising (1) an effective amount of Lactobacillus paracasei, L. paracasei culture medium, or indole-3-lactic acid (ILA); and (2) a physiologically acceptable excipient. The composition is effective for improving liver health or for treating or preventing metabolic dysfunction-associated steatotic liver disease (MASLD). Also provided are corresponding methods and kits for the prophylactic or therapeutic uses against liver diseases such as MASLD.
Need to check novelty before this filing date? Find Prior Art